The Cyclin Dependent Kinase 9 pipeline drugs market research report outlays comprehensive information on the Cyclin Dependent Kinase 9 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Cyclin Dependent Kinase 9 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Infectious Disease, Respiratory, and Immunology which include the indications Solid Tumor, Breast Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Epstein–Barr Virus (HHV-4) Infections, Idiopathic Pulmonary Fibrosis, and Rheumatoid Arthritis. It also reviews key players involved in Cyclin Dependent Kinase 9 targeted therapeutics development with respective active and dormant or discontinued products.
The Cyclin Dependent Kinase 9 pipeline targets constitutes close to 31 molecules. Out of which, approximately 25 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical, and Discovery stages are 1, 9, 4, 9, and 2 respectively. Similarly, the universities portfolio in Phase I, Preclinical, and Discovery comprises 1, 3, and 2 molecule.
Cyclin Dependent Kinase 9 overview
Cyclin-dependent kinase 9 (CDK9) is a cyclin-dependent kinase associated with P-TEFb. This kinase was found to be a component of the multiprotein complex TAK/P-TEFb, which is an elongation factor for RNA polymerase II-directed transcription and functions by phosphorylating the C-terminal domain of the largest subunit of RNA polymerase II. This protein forms a complex with and is regulated by its regulatory subunit cyclin T or cyclin K. HIV-1 Tat protein was found to interact with CDK9 and cyclin T, which suggested a possible involvement of this protein in AIDS.
For a complete picture of Cyclin Dependent Kinase 9’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
